Haemonetics Corporation Stock News

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Integra expands the international reach of the CUSA platform and registers DuraGen, DuraSeal, Mayfield and Duo LED lighting in the EMEA and Latin America.

Investors are optimistic about Haemonetics (HAE) on consistent growth performance and raised guidance.

The heavy selling pressure might have exhausted for Haemonetics (HAE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts

Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Investors are optimistic about Haemonetics (HAE), driven by a strategic focus on establishing leading positions in high-growth markets and raised guidance.

Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Haemonetics has seen signs of growth and operational momentum after a challenging period during the pandemic. The company's fiscal year 2024 first half results were solid, increasing its appeal. Still

Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Stryker (SYK). But which of these two companies is the best option for those looking fo

Haemonetics (HAE) could produce exceptional returns because of its solid growth attributes.

Haemonetics Corporation (NYSE:HAE ) Q2 2024 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Olga Guyette – Senior Director, Investor Relations and Treasury Chris Simon –

The robust volume growth and price benefits in the Plasma business driven by strong momentum in U.S. collections and price benefit Haemonetics' (HAE) fiscal second-quarter results.

Haemonetics (HAE) could produce exceptional returns because of its solid growth attributes.

Investors are optimistic about Haemonetics (HAE) on robust volume growth in the Plasma business and upbeat guidance.